Reduction of costs for anemia-management drugs associated with the use of ferric citrate

BACKGROUND: Ferric citrate is a novel phosphate binder which has the potential to reduce usage of erythropoietin-stimulating agents (ESAs) and intravenous (IV) iron used for anemia management during hemodialysis (HD) among patients with end-stage renal disease (ESRD). Currently, the potential health...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Anila, Peterson, Leif E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038453/
https://www.ncbi.nlm.nih.gov/pubmed/24899820
http://dx.doi.org/10.2147/IJNRD.S65158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038453/
https://www.ncbi.nlm.nih.gov/pubmed/24899820
http://dx.doi.org/10.2147/IJNRD.S65158

Ejemplares similares